Carna Biosciences Inc
TSE:4572
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
JP |
Carna Biosciences Inc
TSE:4572
|
7.5B JPY | -4.5 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
223B USD | 26.4 | ||
US |
Danaher Corp
NYSE:DHR
|
185.2B USD | 26.6 | ||
US |
Agilent Technologies Inc
NYSE:A
|
42.3B USD | 21.3 | ||
CH |
Lonza Group AG
SIX:LONN
|
38B CHF | 27.4 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.5B USD | 19.2 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 33.4 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
27.5B USD | 27.9 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25.9B USD | 35.4 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.8B USD | 19.6 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 29.8 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.